Welcome to the June 2015 newsletter of the Lancet Commission on Essential Medicine Policies

Driving the Commission Forward- Recent updates
Since the Commission has launched, several key events have taken place driving the momentum, and awareness of The Lancet Commission on Essential Medicine Policies and our recommendations. One of most recent examples:

Launch of the 19th WHO Model Essential Medicine List
On May 8th the WHO has published the 19th Model Essential Medicine list including new medicines. The inclusion of high-cost medicines in the List shows the need for a new model of research and development (R&D) which promotes the development of affordable medicines for all and the need to link these models with health system financing. Both topics will be featured in the Lancet report. Commissioners are also discussing the implication of the updated WHO Model Essential Medicine List on other topics such as financing, selection, service delivery and ensuring safe and efficient use.

November 2015 Lancet Commission EMP Meeting
The next Lancet Commission EMP meeting will take place in Amsterdam in November 2015. The objective of the meeting is to present the drafts of each of the main sections of the report and discuss key recommendations.

Stay tuned for more updates!

Recent Publications of Interest
- There are approximately 4 billion people worldwide that are exposed to ineffective, falsified, and substandard drugs being sold as authorized and genuine medicines. The American Journal of Tropical Medicine and Hygiene recently launched a series featuring 16 articles on “The Global Pandemic of Falsified Medicines: Laboratory and Field Innovations and Policy Perspectives”
  http://www.ajtmh.org/content/92/6_Suppl
- The World Bank and WHO recently published a report on “Tracking universal coverage: First Global Monitoring Report” featuring the importance of UHC and medicines, research and development for NTDs
and disparity of coverage rates and access to medicines
http://apps.who.int/iris/bitstream/10665/174536/1/9789241564977_eng.pdf?ua=1

Upcoming Events and News relevant to Essential Medicine Policies

- United Nations Summit to adopt the post 2015 Development Agenda, 25-27 September, New York, USA

- Prince Mahidol Award Conference, 26-31 January 2016, Bangkok, Thailand – Priority Setting for Universal Health Coverage
  http://www.pmaconference.mahidol.ac.th/

Spotlight
Lancet EMP Commissioner: Dr. Jing Sun

sunjingx@yahoo.com

Jing Sun is an associate professor of pharmaceutical policy at Peking Union Medical College (PUMC) School of Public Health. She is also the leader of Pharmaceutical Policy Theme Group of China Core Group of the International Network Rational Use of Drug (INRUD) and the country leader of BRICS Medicines Alliance.

The extensive work experiences in national lab, national regulatory authority, international health organization, research and academic institutes render her knowledge and skills in pharmaceutical science, project management and policy research. Her research areas focus on macro pharmaceutical policy and initiatives to improve the use of medicines. Since 2004, she has been involved in providing technical support to the Chinese government in the pharmaceutical area, and contributed to China’s national health system reform, especially the reforms in the pharmaceutical sector.

Dr. Sun received her Ph.D. from the Graduate School of Medical Sciences at the University of Groningen. She received her MSc. of International Health Policy from London School of Economics and her Bachelor of Pharmaceutical Chemistry from Peking University.